Walkaway automation for greater efficiency
With Vanadis technology, all the critical steps are automated, starting with pipetting steps to reduce manual errors. Plasma volumes are monitored by camera to avoid contamination by the buffy coat, and samples and reagents are barcoded for complete tracking throughout the workflow. Our software guides you through the process, with user-friendly touchscreens, enabling remote workflow management for ease of use. Easy to integrate, our software is designed for LIMS connectivity, reducing manual errors while simplifying data management.


Groundbreaking cfDNA technology: No PCR, no sequencing
Vanadis is the only NIPT screening platform to enable targeted cfDNA analysis without PCR, instead directly capturing target fragments and labeling them for counting. A proprietary nanofilter plate then captures labeled molecules for imaging, eliminating the need for data-intensive steps such as DNA sequencing, microarrays, and microfluidics.
Workflow: Streamlined workflow from primary tube to final result
Screen for the risk of trisomies 21, 18, 13 & sex chromosome aneuploidies as well as fetal sex determination with Vanadis NIPT. By targeting thousands of chromosomal sequences, the Vanadis system can bring high precision non-invasive prenatal testing to your lab, counting an average of 650,000 molecules per chromosome.

Benefits for your laboratory
Kits: Proven performance
Studies have demonstrated that the Vanadis NIPT system could improve detection and false positive rates, while minimizing the number of no-calls.
Products comprising the Vanadis NIPT system are CE-marked in vitro diagnostic products in accordance with European directive 98/79/EC.
Sample outcome | ||||
---|---|---|---|---|
Vanadis NIPT result |
Trisomy 21 |
Trisomy 18 |
Trisomy 13 |
SCA |
Detection rate (95% CI) |
99% (99/100) (94.6%-100.0%) |
92.9% (26/28) (76.5%-99.1%) |
88.9% (16/18) (65.3%-98.6%) |
84.0% (21/25) (63.9%-95.5%) |
False positive rate (95% CI) |
0.0% (0/2032) (0.0%-0.18%) |
0.4% (8/2032) (0.17%-0.77%) |
0.3% (5/2032) (0.08%-0.57%) |
1.0% (20/2015) (0.6%-1.5%) |
Observed no-call rate for 21/28/13 after first pass: 0.95% |
||||
Observed no-call rate for SCA after first pass: 1.13% |
Source: Vanadis Core™ Reagent Cartridge II, kit insert Version #1.
Leading risk calculation software
Related products

